StreetInsider.com News Articles

Form SCHEDULE 13G/A Black Diamond Therapeuti Filed by: T. Rowe Price Investment Management, Inc.

Wed, 08 Jul 2026 11:30:00 -0400

si-local-file:///var/storage/secattach/20260708/26746229.html

Form SCHEDULE 13G/A Black Diamond Therapeuti Filed by: T. Rowe Price Investment Management, Inc.

Wed, 08 Jul 2026 11:30:00 -0400

si-local-file:///var/storage/secattach/20260708/26746229.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Behbahani Ali

Mon, 29 Jun 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260629/26707097.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Behbahani Ali

Mon, 29 Jun 2026 16:40:00 -0400

si-local-file:///var/storage/secattach/20260629/26707097.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Kulkarni Samarth

Mon, 29 Jun 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260629/26707042.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Kulkarni Samarth

Mon, 29 Jun 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260629/26707042.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Menzel Garry E

Mon, 29 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260629/26707028.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Menzel Garry E

Mon, 29 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260629/26707028.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Raman Prakash

Mon, 29 Jun 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260629/26707011.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Raman Prakash

Mon, 29 Jun 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260629/26707011.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Dhingra Kapil

Mon, 29 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260629/26706973.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Dhingra Kapil

Mon, 29 Jun 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260629/26706973.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Campbell Shannon

Mon, 29 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260629/26706954.html

Form 4 Black Diamond Therapeuti For: Jun 26 Filed by: Campbell Shannon

Mon, 29 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260629/26706954.html

Form 8-K Black Diamond Therapeuti For: Jun 26

Mon, 29 Jun 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260629/26706746.html

Form 8-K Black Diamond Therapeuti For: Jun 26

Mon, 29 Jun 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260629/26706746.html

Form 4 Black Diamond Therapeuti For: Jun 19 Filed by: Behbahani Ali

Mon, 22 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260622/26673389.html

Form 4 Black Diamond Therapeuti For: Jun 19 Filed by: Behbahani Ali

Mon, 22 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260622/26673389.html

Form 4 Black Diamond Therapeuti For: Jun 19 Filed by: Raman Prakash

Mon, 22 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260622/26673022.html

Form 4 Black Diamond Therapeuti For: Jun 19 Filed by: Raman Prakash

Mon, 22 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260622/26673022.html

Raymond James: 'The topline numbers presented by Black Diamond today indicate that the company has a viable asset in our view'

Fri, 22 May 2026 09:38:44 -0400

Raymond James analyst Sean McCutcheon reiterated an Outperform rating and $11.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).

The analyst comments "Thursday, after market close, ASCO 2026 regular abstracts were released, and in conjunction Black Diamond reported the topline result for the longer-term follow-up from their Phase 2 study testing silevertinib in 1L non-classical EGFR mutant (EGFR NCM) NSCLC. Management also hosted a call to discuss the disclosure. Recall we previously saw the initial response rate data during December 2025 (our commentary), which we think hit the mark in a highly heterogenous NCM population, though left some uncertainty on tolerability/ability

Raymond James: 'The topline numbers presented by Black Diamond today indicate that the company has a viable asset in our view'

Fri, 22 May 2026 09:38:44 -0400

Raymond James analyst Sean McCutcheon reiterated an Outperform rating and $11.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).

Stifel Defending Black Diamond Therapeutics (BDTX): 'we believe investors are underappreciating the breadth of mutation silevertinib is showing'

Fri, 22 May 2026 09:37:35 -0400

Stifel analyst Laura Prendergast reiterated a Buy rating and $8.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).

The analyst comments "We view the preliminary median PFS of 15.2 months as highly encouraging and perhaps practice changing - the DoR had not yet been reached. 44% of patients are progression free/still on drug with median follow up ~9.8 months, suggesting PFS could increase with longer follow up. What stands out to us the most is: • The breadth of mutations seen in patients who are progression free for ≥1 year (10 unique mutations across 8 patients). • The lack of any

Stifel Defending Black Diamond Therapeutics (BDTX): 'we believe investors are underappreciating the breadth of mutation silevertinib is showing'

Fri, 22 May 2026 09:37:35 -0400

Stifel analyst Laura Prendergast reiterated a Buy rating and $8.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).

TD Cowen on Black Diamond Therapeutics (BDTX) Amid 18% Drop: 'is unclear if the FDA will require Ph3 run-in or additional Ph2 dosing work extending competitor's lead'

Fri, 22 May 2026 09:36:24 -0400

TD Cowen analyst Marc Frahm reiterated a Buy rating and {REMOVEPT} price target on Black Diamond Therapeutics (NASDAQ: BDTX).

The analyst comments "BDTX shared updated 1L data for 200mg silevertinib, including a preliminary mPFS of 15.2m, 60% ORR (86% CNS), and slightly increased dose-reduction of 84%. Mgmt plans to discuss Ph3 pivotal plans including a proposed 150mg dose with the FDA in H2. While 150mg dose selection appears wise, it is unclear if the FDA will require Ph3 run-in or additional Ph2 dosing work extending competitor's lead."

For an analyst ratings summary and ratings history on Black Diamond Therapeutics click here.